io102-io103

Urothelial Carcinoma Bladder

IO BiotechPhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

12 Active assets in the Urothelial Carcinoma Bladder cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Fred Hutchinson Cancer Center	Phase 3	BB
9mw2821 Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 2	CCC
tamivarotene Nagoya University	Phase 2	CCC
Toripalimab Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 2	CCC
Nivolumab Nagoya University	Phase 2	CCC

View all 19 →

Same molecule, other indications

io102-io103 is also rated in:

melanomaDormant

B

Indicative ·

56 / 100

metastatic melanomaDormant

CCC

Indicative ·

54 / 100

head and neck squamous cell carcinomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.